[Natural killer (NK) and lymphokine-activated killer (LAK) activities of a patient recovered from bladder cancer, and the characteristics of LAK cells generated from lymphocyte subsets]
- PMID: 7553054
- DOI: 10.2177/jsci.18.197
[Natural killer (NK) and lymphokine-activated killer (LAK) activities of a patient recovered from bladder cancer, and the characteristics of LAK cells generated from lymphocyte subsets]
Abstract
NK and LAK activities of a patient who recovered from bladder transitional cell carcinoma were determined. He was diagnosed in 1980 and operations, radiations and chemotherapies were repeated until 1986. Since 1987, a relapse has not been recognized, and he is now in a tumor free state. Recently, his very high NK and LAK activities were found. The percentage of CD 16+ in his peripheral blood lymphocytes (PBL) was 52.9%, the CD 4- CD 8- CD 16+ was 26.6% (17.5% and 12.1% in control, respectively). It seems likely that his tumor free condition may be related to these high killer activities. As a high number of CD 4- CD 8- cells were included in his PBL, it was possible to generate a CD 4- CD 8(-)-LAK and compare it with the CD 8(+)-LAK. The CD 4- CD 8(-)-LAK exhibited higher killer activity which was maintained for a long period of the culture, and a strong adherence property against the cultured tumor cells. Whereas, the CD 8(+)-LAK did not show such a high level of killer activity which decreased after two weeks into the culture. However, the CD 8(+)-LAK in this patient demonstrated higher killer activity against the auto-tumor cell line compared to what occurred with the control. A type of specific killing against auto-tumor cells may be contained in his CD 8(+)-LAK, although the MHC-restrictive killing was not confirmed. It remains unclear why the killer activities increased in this patient.
Similar articles
-
Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.Clin Immunol Immunopathol. 1995 Oct;77(1):75-81. doi: 10.1016/0090-1229(95)90139-6. Clin Immunol Immunopathol. 1995. PMID: 7554487
-
Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.J Clin Immunol. 1990 Nov;10(6):311-20. doi: 10.1007/BF00917476. J Clin Immunol. 1990. PMID: 1707414
-
LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.Nat Immun. 1992 Jan-Feb;11(1):7-16. Nat Immun. 1992. PMID: 1611282
-
Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.Jpn J Clin Oncol. 1990 Mar;20(1):87-93. Jpn J Clin Oncol. 1990. PMID: 2108272
-
Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection.Vet Immunol Immunopathol. 2016 Sep;177:58-63. doi: 10.1016/j.vetimm.2016.06.007. Epub 2016 Jun 16. Vet Immunol Immunopathol. 2016. PMID: 27436446
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials